Xeris Biopharma Holdings, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Xeris Biopharma Holdings, Inc. now
Current reporting with the operating signal separated from the noise.
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?
Investors are testing whether Xeris Biopharma Holdings, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript
Investors are testing whether Xeris Biopharma Holdings, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript
Investors are testing whether Xeris Biopharma Holdings, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Xeris Biopharma Holdings, Inc. Rings the Closing Bell
The story matters when it changes Xeris Biopharma Holdings, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest XERS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Xeris Biopharma Holdings, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →